



## Product Datasheet

<b>Product Name</b>	Vascular Endothelial Growth Factor Receptor-2 Human Recombinant
<b>Cata No</b>	CB500848
<b>Source</b>	<i>Insect Cells</i>
<b>Synonyms</b>	KDR D1-7, sKDR D1-7, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2.

### Description

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.

Differential splicing of the *flt-1* gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF<sub>165</sub> to VEGFR-2 is dependent on heparin. Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.

The sKDR is purified by proprietary chromatographic techniques.

### Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

### Biological Activity

The activity of VEGFR-2<sub>D1-7</sub> was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED<sub>50</sub> for this effect is typically 10.0 ng/ml.

### Purity

Greater than 95.0% as determined by:  
(a) Analysis by RP-HPLC.  
(b) Analysis by SDS-PAGE.

### Formulation

KDR was lyophilized from a concentrated (1 mg/ml) sterile solution containing 25mM MES pH-5.5 and 100mM NaCl.

### Reconstitution

It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

### Stability

Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2-7 days and for future use below -18°C.

For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

**\* For Non-Clinical Research Use Only \***



# California Bioscience

---

83103 Avenue 48, Ste.1B #204  
Coachella, CA 92236 USA  
Phone : +1.6268339877  
Email : [info@cali-bio.com](mailto:info@cali-bio.com)

Please prevent freeze-thaw cycles.

**Product Datasheet**

**\* For Non-Clinical Research Use Only \***